Category: Cancer Types

Home / Cancer Types

Categories

Chen Yan Story – Cured of beta thalassemia using CRISPR gene therapy

A significant breakthrough for the medical field and those suffering from sickle cell disease (SCD) and thalassemia, an innovative gene therapy employing CRISPR/Cas9 technology has exhibited an extrao...

LungVax: Lung cancer vaccine

Lung cancer vaccine The 'LungVax' vaccine, developed by researchers from the University of Oxford, the Francis Crick Institute, and University College London, employs technology akin to that of the v...

Gamma Delta (γδ) T cells as a potential treatment for glioblastoma

IntroductionDespite being a minority among T cells, γδ T cells play crucial roles in immune defense against infections and in the suppression of malignancies. T cells have the potential to be a good...

World-first lung cancer vaccine trials started in seven countries

August 2024: Medical professionals have initiated clinical trials for the first-ever mRNA lung cancer vaccine, which has been praised by specialists for its revolutionary ability to potentially rescue...

Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer

August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, I...

Neoadjuvant/adjuvant durvalumab is approved by the USFDA for resectable non-small cell lung cancer

August 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca) in combination with platinum-containing chemotherapy as a neoadjuvant treatment, fol...

The FDA has broadened the indication for dostarlimab-gxly to include the treatment of endometrial cancer in combination with chemotherapy

August 2024: The Food and Drug Administration has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for t...

The FDA has granted approval for the use of daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of multiple myeloma

July 2024: The Food and Drug Administration (FDA) has granted approval for the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in conjunction with ...

The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma

June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurr...

CAR T Cell Therapy for Blood Cancers

 IntroductionBlood cancers, also known as hematologic malignancies, include leukemia, lymphoma, and multiple myeloma. These cancers have their origins in either bone marrow or the lymphatic system an...

Scan the code